226 related articles for article (PubMed ID: 35266417)
1. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J; Hauser SL; Bar-Or A; Montalban X; Cohen JA; Cross AH; Deiva K; Ganjgahi H; Häring DA; Li B; Pingili R; Ramanathan K; Su W; Willi R; Kieseier B; Kappos L
Mult Scler; 2022 Sep; 28(10):1562-1575. PubMed ID: 35266417
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
[TBL] [Abstract][Full Text] [Related]
4. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
[TBL] [Abstract][Full Text] [Related]
6. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J
Front Immunol; 2022; 13():852563. PubMed ID: 35432382
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
Kang C; Blair HA
Drugs; 2022 Jan; 82(1):55-62. PubMed ID: 34897575
[TBL] [Abstract][Full Text] [Related]
9. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
[TBL] [Abstract][Full Text] [Related]
10. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
[TBL] [Abstract][Full Text] [Related]
14. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
15. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
[TBL] [Abstract][Full Text] [Related]
17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
18. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
19. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS;
Mult Scler; 2012 Nov; 18(11):1625-32. PubMed ID: 22723573
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
Cohan S; Tencer T; Arndorfer S; Zhu X; Zivkovic M; Kumar J
Mult Scler Relat Disord; 2021 Jul; 52():102972. PubMed ID: 33979770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]